CellScape

CellScape is a biotech startup focused on revolutionizing prenatal genetic testing with their pioneering whole fetal cell technology. The company, formerly known as Saryna Medical Corp, is situated in the thriving biotech hub of Newark, California. Founded in 2008, CellScape's primary mission is to make comprehensive prenatal genetic testing accessible to all women without the need for invasive procedures that could pose risks to the fetus. The leadership team's successful track record in bringing innovative and cost-effective medical and molecular diagnostics to the market adds credibility to the venture. Their latest funding round was a Series B investment on May 10, 2013. Despite the absence of specific investors provided, this investment demonstrates ongoing support and interest in their groundbreaking technology. With a focus on biotechnology and healthcare, CellScape holds promise for making significant strides in improving prenatal care and genetic screening.